Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.


Journal

Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794

Informations de publication

Date de publication:
05 2022
Historique:
received: 15 01 2021
accepted: 07 04 2021
pubmed: 1 4 2022
medline: 21 4 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Predictive factors for intrahepatic cholangiocarcinoma in long-term follow-up of hepatolithiasis are unknown. We thus conducted a cohort study to investigate the predictive factors for developing intrahepatic cholangiocarcinoma in hepatolithiasis. This cohort is comprised of 401 patients registered in a nationwide survey of hepatolithiasis for 18 years of follow-up. Cox regression analysis was used to elucidate predictive factors for developing intrahepatic cholangiocarcinoma. The median follow-up period of patients was 134 months. Twenty-two patients developed intrahepatic cholangiocarcinoma and all died. Identified independent significant factors were as follows: age 63 years or older (hazard ratio [HR] 3.344), residual stones at the end of treatment (HR 2.445), and biliary stricture during follow-up (HR 4.350). The incidence of intrahepatic cholangiocarcinoma in patients with three factors was significantly higher than that in patients with one or two factors. The incidence in the groups with one or two predictive factors was not different. In 88.9% of patients with both biliary stricture and intrahepatic cholangiocarcinoma, the duration between the diagnoses of biliary stricture and intrahepatic cholangiocarcinoma was ≥ 5 years. However, once intrahepatic cholangiocarcinoma developed, 77.8% of patients died within 1 year. Of 24 patients with no symptoms, no previous choledocoenterostomy, no signs of malignancy, no biliary stricture, and no treatment for hepatolithiasis during follow-up, only one developed intrahepatic cholangiocarcinoma. Regarding carcinogenesis, complete stone clearance and releasing biliary stricture can prevent the development of intrahepatic cholangiocarcinoma and improve the prognosis of hepatolithiasis.

Sections du résumé

BACKGROUND
Predictive factors for intrahepatic cholangiocarcinoma in long-term follow-up of hepatolithiasis are unknown. We thus conducted a cohort study to investigate the predictive factors for developing intrahepatic cholangiocarcinoma in hepatolithiasis.
METHODS
This cohort is comprised of 401 patients registered in a nationwide survey of hepatolithiasis for 18 years of follow-up. Cox regression analysis was used to elucidate predictive factors for developing intrahepatic cholangiocarcinoma.
RESULTS
The median follow-up period of patients was 134 months. Twenty-two patients developed intrahepatic cholangiocarcinoma and all died. Identified independent significant factors were as follows: age 63 years or older (hazard ratio [HR] 3.344), residual stones at the end of treatment (HR 2.445), and biliary stricture during follow-up (HR 4.350). The incidence of intrahepatic cholangiocarcinoma in patients with three factors was significantly higher than that in patients with one or two factors. The incidence in the groups with one or two predictive factors was not different. In 88.9% of patients with both biliary stricture and intrahepatic cholangiocarcinoma, the duration between the diagnoses of biliary stricture and intrahepatic cholangiocarcinoma was ≥ 5 years. However, once intrahepatic cholangiocarcinoma developed, 77.8% of patients died within 1 year. Of 24 patients with no symptoms, no previous choledocoenterostomy, no signs of malignancy, no biliary stricture, and no treatment for hepatolithiasis during follow-up, only one developed intrahepatic cholangiocarcinoma.
CONCLUSIONS
Regarding carcinogenesis, complete stone clearance and releasing biliary stricture can prevent the development of intrahepatic cholangiocarcinoma and improve the prognosis of hepatolithiasis.

Identifiants

pubmed: 35357571
doi: 10.1007/s00535-022-01868-6
pii: 10.1007/s00535-022-01868-6
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

387-395

Informations de copyright

© 2022. Japanese Society of Gastroenterology.

Références

Suzuki Y, Mori T, Yokoyama M, et al. A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort. J Gastroenterol. 2018;53:854–60.
doi: 10.1007/s00535-017-1410-6
Tazuma S, Unno M, Igarashi Y, et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300.
doi: 10.1007/s00535-016-1289-7
Huang MH, Chen CH, Yang JC, et al. Long-term outcome of percutaneous transhepatic cholangioscopic lithotomy for hepatolithiasis. Am J Gastroenterol. 2003;98:2655–62.
doi: 10.1111/j.1572-0241.2003.08770.x
Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:567–75.
Meng ZW, Han SH, Zhu JH, et al. Risk factors for cholangiocarcinoma after initial hepatectomy for intrahepatic stones. World J Surg. 2017;41:835–43.
doi: 10.1007/s00268-016-3752-2
Cheon YK, Cho YD, Moon JH, et al. Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis. Surgery. 2009;146:843–53.
doi: 10.1016/j.surg.2009.04.009
Park JS, Jeong S, Lee DH, et al. Risk factors for long-term outcomes after initial treatment in hepatolithiasis. J Korean Med Sci. 2013;28:1627–31.
doi: 10.3346/jkms.2013.28.11.1627
Lee TY, Chen YL, Chang HC, et al. Outcomes of hepatectomy for hepatolithiasis. World J Surg. 2007;31:479–82.
doi: 10.1007/s00268-006-0441-6
Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993;71:2461–5.
doi: 10.1002/1097-0142(19930415)71:8<2461::AID-CNCR2820710806>3.0.CO;2-7
Uenishi T, Hamba H, Takemura S, et al. Outcomes of hepatic resection for hepatolithiasis. Am J Surg. 2009;198:199–202.
doi: 10.1016/j.amjsurg.2008.08.020
Zhu QD, Zhou MT, Zhou QQ, et al. Diagnosis and surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma. World J Surg. 2014;38:2097–104.
doi: 10.1007/s00268-014-2476-4
Su CH, Shyr YM, Lui WY, et al. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84:969–73.
doi: 10.1002/bjs.1800840717
Ohta T, Nagakawa T, Konishi I, et al. Clinical experience of intrahepatic cholangiocarcinoma associated with hepatolithiasis. Jpn J Surg. 1988;18:47–53.
doi: 10.1007/BF02470846
Kim HJ, Kim JS, Suh SJ, et al. Cholangiocarcinoma risk as long-term outcome after hepatic resection in the hepatolithiasis patients. World J Surg. 2015;39:1537–42.
doi: 10.1007/s00268-015-2965-0
Jo JH, Chung MJ, Park JY, et al. High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study. Surg Endosc. 2013;27:4210–6.
doi: 10.1007/s00464-013-3025-1
Lee JY, Kim JS, Moon JM, et al. Incidence of cholangiocarcinoma with or without previous resection of liver for hepatolithiasis. Gut Liver. 2013;7:475–9.
doi: 10.5009/gnl.2013.7.4.475
Suzuki Y, Mori T, Abe N, et al. Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on the basis of Japanese Multicenter study. Hepatol Res. 2012;42:166–70.
doi: 10.1111/j.1872-034X.2011.00908.x
Kubo S, Kinoshita H, Hirohashi K, et al. Hepatolithiasis associated with cholangiocarcinoma. World J Surg. 1995;19:637–41.
doi: 10.1007/BF00294744
Miyazaki T, Shinkawa H, Takemura S, et al. Precancerous lesions and liver atrophy as risk factors for hepatolithiasis—related death after liver resection for hepatolithiasis. Asian Pac J Cancer Prev APJCP. 2020;21:3647–54.
doi: 10.31557/APJCP.2020.21.12.3647
Suzuki Y, Mori T, Yokoyama M, et al. Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years. J Hepato-Biliary Pancreat Sci. 2014;21:617–22.
doi: 10.1002/jhbp.116
Tsuyuguchi T, Miyakawa K, Sugiyama H, et al. Ten-year long-term results after non-surgical management of hepatolithiasis, including cases with choledochoenterostomy. J Hepato-Biliary Pancreat Sci. 2014;21:795–800.
doi: 10.1002/jhbp.134
Liu ZY, Zhou YM, Shi LH, et al. Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study. Hepatobiliary Pancreat Dis Int HBPD INT. 2011;10:626–31.
doi: 10.1016/S1499-3872(11)60106-9
Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology. 2003;50:8–12.
Koga A, Ichimiya H, Yamaguchi K, et al. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer. 1985;55:2826–9.
doi: 10.1002/1097-0142(19850615)55:12<2826::AID-CNCR2820551219>3.0.CO;2-1
Kim HJ, Kim JS, Joo MK, et al. Hepatolithiasis and intrahepatic cholangiocarcinoma: a review. World J Gastroenterol. 2015;21:13418–31.
doi: 10.3748/wjg.v21.i48.13418
Kusano T, Isa T, Ohtsubo M, et al. Natural progression of untreated hepatolithiasis that shows no clinical signs at its initial presentation. J Clin Gastroenterol. 2001;33:114–7.
doi: 10.1097/00004836-200108000-00004

Auteurs

Yutaka Suzuki (Y)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Toshiyuki Mori (T)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. mori@ks.kyorin-u.ac.jp.

Hirokazu Momose (H)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Ryota Matsuki (R)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Masaharu Kogure (M)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Nobutsugu Abe (N)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Hiroyuki Isayama (H)

Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Susumu Tazuma (S)

JA Onomichi General Hospital, Hiroshima, Japan.

Atsushi Tanaka (A)

Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Hajime Takikawa (H)

Teikyo University Faculty of Medical Technology, Tokyo, Japan.

Yoshihiro Sakamoto (Y)

Department of Gastrointestinal and General Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH